Literature DB >> 29852382

Widely targeted metabolomics of Alzheimer's disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry.

Yoshio Muguruma1, Haruhito Tsutsui2, Takumi Noda2, Hiroyasu Akatsu3, Koichi Inoue4.   

Abstract

Confirmed biomarkers of postmortem cerebrospinal fluid (pCSF) are used to differentiate between Alzheimer's disease (AD) patients and healthy seniors with high diagnostic accuracy. However, the extent to which the performance of specific metabolic profiling facilitates reliable estimations of the concentrations of the different pCSF biomarkers and their ratios remains unclear. The interpretation of the lower levels of molecules of metabolic profiling and their concentration ratios in pCSF related to brain disorders could facilitate an unchallenging detection of peripheral biomarkers of AD stages and other dementia types. In this study, we proposed the use of widely targeted metabolomics for pCSF metabolic profiling using 9-fluorenylmethyl chloroformate- (FMOC) derivatized ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) to evaluate the diversity of 97 amine-mediated metabolic patterns and pathways from confirmed diagnosis based on AD brain pathology. Our results identified the metabolites that contributed toward and mutually influenced the principal component analysis plot with integrated analytes. Furthermore, the AD group showed a significant variation in several analyte concentration levels compared to those of control subjects. These trends of the concentration levels expressed by the amine metabolic pathways indicated the decreased activity of polyamine and tryptophan-kynurenine (Trp-Kyn) metabolisms. Moreover, increased metabolites such as methionine sulfoxide, 3-methoxy-anthranilate, cadaverine, guanine, and histamine were observed by widely targeted metabolomics of pCSF from the AD subjects. According to their metabolic pathway analysis using FMOC-derivatized UHPLC-MS/MS assay, we supposed that the involvement of polyamine and Trp-Kyn metabolisms was observed in the pCSF samples.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  9-Fluorenylmethyl chloroformate; Alzheimer's disease; Cerebrospinal fluid; Ultra-high performance liquid chromatography tandem mass spectrometry; Widely targeted metabolomics

Mesh:

Substances:

Year:  2018        PMID: 29852382     DOI: 10.1016/j.jchromb.2018.05.031

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  9 in total

Review 1.  Review of recent developments in GC-MS approaches to metabolomics-based research.

Authors:  David J Beale; Farhana R Pinu; Konstantinos A Kouremenos; Mahesha M Poojary; Vinod K Narayana; Berin A Boughton; Komal Kanojia; Saravanan Dayalan; Oliver A H Jones; Daniel A Dias
Journal:  Metabolomics       Date:  2018-11-17       Impact factor: 4.290

2.  Small phenolic and indolic gut-dependent molecules in the primate central nervous system: levels vs. bioactivity.

Authors:  George E Jaskiw; Dongyan Xu; Mark E Obrenovich; Curtis J Donskey
Journal:  Metabolomics       Date:  2022-01-06       Impact factor: 4.290

3.  A multi-omics analysis for the prediction of neurocognitive disorders risk among the elderly in Macao.

Authors:  Yan Han; Xingping Quan; Yaochen Chuang; Qiaoxing Liang; Yang Li; Zhen Yuan; Ying Bian; Lai Wei; Ji Wang; Yonghua Zhao
Journal:  Clin Transl Med       Date:  2022-06

Review 4.  Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics.

Authors:  Haorong Li; Martine Uittenbogaard; Ling Hao; Anne Chiaramello
Journal:  Metabolites       Date:  2021-04-10

5.  Characterization of two closely related citrus cultivars using UPLC-ESI-MS/MS-based widely targeted metabolomics.

Authors:  Fu Wang; Lin Chen; Shiwei Chen; Hongping Chen; Youping Liu
Journal:  PLoS One       Date:  2021-07-20       Impact factor: 3.240

Review 6.  Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.

Authors:  Yuqing Liang; Shan Xie; Yanyun He; Manru Xu; Xi Qiao; Yue Zhu; Wenbin Wu
Journal:  Dis Markers       Date:  2022-01-19       Impact factor: 3.434

Review 7.  Challenges in LC-MS-based metabolomics for Alzheimer's disease early detection: targeted approaches versus untargeted approaches.

Authors:  Pierluigi Reveglia; Carmela Paolillo; Gabriella Ferretti; Armando De Carlo; Antonella Angiolillo; Rosarita Nasso; Mafalda Caputo; Carmela Matrone; Alfonso Di Costanzo; Gaetano Corso
Journal:  Metabolomics       Date:  2021-08-28       Impact factor: 4.290

8.  Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer's disease (from the Nakayama Study).

Authors:  Tomoki Ozaki; Yuta Yoshino; Ayumi Tachibana; Hideaki Shimizu; Takaaki Mori; Tomohiko Nakayama; Kazuaki Mawatari; Shusuke Numata; Jun-Ichi Iga; Akira Takahashi; Tetsuro Ohmori; Shu-Ichi Ueno
Journal:  Sci Rep       Date:  2022-09-08       Impact factor: 4.996

Review 9.  Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development.

Authors:  Knut Biber; Anindya Bhattacharya; Brian M Campbell; Justin R Piro; Michael Rohe; Roland G W Staal; Robert V Talanian; Thomas Möller
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.